Efficacy and Safety of Pritelivir vs Foscarnet for the Treatment of Acyclovir-Refractory Herpes Simplex Virus Infection in Immunocompromised Adults: A Randomized, Open-Label Phase 2 Trial.

Kotton CN, Workowski KA, Kumar PN, Avery RK, Chemaly RF, Issa NC, Ramgopal M, Schiffer JT, Albrecht J, O'Neal HR Jr, Chandrasekar P, Schreibman TS, Ramesh M, Ison MG, Sumner ME, Dane A, Surujbally B, Timmler B, Rangaraju M, Papanicolaou GA, Birkmann A, Wald A

Open source

DOI: 10.1093/ofid/ofag539
Published: 2026 Sep
Container: Open forum infectious diseases
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ofid/ofag539,
  title = {Efficacy and Safety of Pritelivir vs Foscarnet for the Treatment of Acyclovir-Refractory Herpes Simplex Virus Infection in Immunocompromised Adults: A Randomized, Open-Label Phase 2 Trial.},
  author = {Kotton CN and Workowski KA and Kumar PN and Avery RK and Chemaly RF and Issa NC and Ramgopal M and Schiffer JT and Albrecht J and O'Neal HR Jr and Chandrasekar P and Schreibman TS and Ramesh M and Ison MG and Sumner ME and Dane A and Surujbally B and Timmler B and Rangaraju M and Papanicolaou GA and Birkmann A and Wald A},
  year = {2026},
  journal = {Open forum infectious diseases},
  doi = {10.1093/ofid/ofag539},
  url = {https://doi.org/10.1093/ofid/ofag539}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Pritelivir vs Foscarnet for the Treatment of Acyclovir-Refractory Herpes Simplex Virus Infection in Immunocompromised Adults: A Randomized, Open-Label Phase 2 Trial.
AU  - Kotton CN
AU  - Workowski KA
AU  - Kumar PN
AU  - Avery RK
AU  - Chemaly RF
AU  - Issa NC
AU  - Ramgopal M
AU  - Schiffer JT
AU  - Albrecht J
AU  - O'Neal HR Jr
AU  - Chandrasekar P
AU  - Schreibman TS
AU  - Ramesh M
AU  - Ison MG
AU  - Sumner ME
AU  - Dane A
AU  - Surujbally B
AU  - Timmler B
AU  - Rangaraju M
AU  - Papanicolaou GA
AU  - Birkmann A
AU  - Wald A
PY  - 2026
JO  - Open forum infectious diseases
DO  - 10.1093/ofid/ofag539
UR  - https://doi.org/10.1093/ofid/ofag539
ER  -

APA

CN, K., KA, W., PN, K., RK, A., RF, C., NC, I., M, R., JT, S., J, A., Jr, O. H., P, C., TS, S., M, R., MG, I., ME, S., A, D., B, S., B, T., M, R., GA, P., A, B., & A, W. (2026). Efficacy and Safety of Pritelivir vs Foscarnet for the Treatment of Acyclovir-Refractory Herpes Simplex Virus Infection in Immunocompromised Adults: A Randomized, Open-Label Phase 2 Trial.. Open forum infectious diseases. https://doi.org/10.1093/ofid/ofag539

Source records

pubmed · retrieved 2026-09-25T02:41:25.378Z